

Remarks

This application is a National Stage Application of International Application Number PCT/JP2004/011951. By this amendment, the applicants have made amendments throughout the specification of the English translation as follows. Page 1, lines 16, 18 and 24 and page 25, line 15 has been amended to correct “URP” to “UPR.” These amendments were made to correct typographical errors in the Japanese specification and should be apparent when read in context. Page 3, line 7 has been amended to delete “/HRD1 (herein after abbreviated as “synoviolin)” for simplicity. Page 3, line 8 has been amended to correct “Hrd1p/Del3” to read “Hrd1;/Del3p.” This amendment was made to correct a typographical error in the Japanese specification and should be apparent when read in context. Page 4, lines 28-33 has been amended to correct an obvious typographical error. Page 14, lines 19 and 27, have been amended to correct “iRNA” to read as “RNAi.” These amendments were made to correct typographical errors in the Japanese specification and should be apparent when read in context. Page 17, line 9 has been amended to correct “SES-PAGE” to read as “SDS-PAGE.” This amendment was made to correct a typographical error in the Japanese specification and should be apparent when read in context. Page 17, line 17 has been amended to include “fetal” before liver. This amendment was made for further clarification, support for which can be found at page 23, lines 26-27. Page 22, lines 30-31, “obtained from E10.5” has been amended to read “syno^{-/-} embryos at E10.5.” This amendment was made for further clarification and support can be found at page 22, lines 27-29. Page 23, line 15 “the liver was stained” has been amended to read as “the cytocentrifuge preparations of fetal liver were stained.” This amendment was made for further clarification and support can be found at page 22, lines 27-29. Tables 2 and 3 have been amended “+/-”, “+/-”, and “-/-” to read “syno +/+”, “syno +/-”, and “syno -/-”. These amendments were made for further clarification and support can be found at page 23, lines 5-9 and lines 15-19. The applicants have further

amended the application by including a "Cross-Reference to a Related Application Section."


No new matter has been added by these amendments.

Claims 1-18 were pending in the subject international patent application. By this Amendment, claims 1 and 14 have been amended and new claims 19-22 have been added. Claim 1 has been amended to correct an obvious typographical error and claim 14 has been amended in order to remove multiple dependencies. Support for the new claims 19-22 can be found in the original claims. Accordingly, claims 1-22 are before the examiner for consideration. No new matter has been added by these Amendments.

Please note that a complete translation of the subject application is also attached with this Preliminary Amendment.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§§1.16, 1.17, or 1.492 as required by this paper to Deposit Account No. 19-0065.

Respectfully Submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address: Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

DRS/la

Attachment: English translation of PCT/JP2004/002920